Gazette

Published by the Commonwealth of Australia

GOVERNMENT NOTICES

COMMONWEALTH OF AUSTRALIA

Department of Health

Therapeutic Goods Administration

THERAPEUTIC GOODS ACT 1989

DESIGNATION OF BLINATUMOMAB AS AN ORPHAN DRUG

I, Dr Anthony Gill, Delegate of the Secretary for the purposes of 16J of the Therapeutic Goods Regulations 1990 ("the Regulations"), acting under subregulation 16J(2) of the Regulations, designate Blinatumomab as an orphan drug on 20 November 2013 for the treatment of B-precursor acute lymphoblastic leukaemia .

The dose form of Blinatumomab for this indication is powder for reconstitution, injection.

The sponsor of Blinatumomab is Amgen Australia Pty Ltd.

(Signed by)

Dr Anthony Gill Office of Scientific Evaluation Delegate of the Secretary

20 November 2013

PO Box 100 Woden ACT 2606 ABN 40 939 406 804

Phone: 02 6232 8444 Fax: 02 6203 1605 Email: info@tga.gov.au Website: http://www.tga.gov.au